Tag: Drug Development

Drug development is the process of bringing a new pharmaceutical drug to the market once a lead compound has been identified through the process of drug discovery. It includes pre-clinical research on microorganisms and animals, filing for regulatory status for an investigational new drug to initiate clinical trials on humans, and may include the step of obtaining regulatory approval with a new drug application to market the drug.

Innovest Global launches its Biotech and Health Services division

Innovest Global launched its anticipated Biotechnology & Health Services Division with the acquisition of a twenty percent interest in StemVax Therapeutics.

Taconic Biosciences and Cyagen Biosciences enter into strategic partnership

Taconic Biosciences and Cyagen Biosciences, global leaders in the generation of custom genetically engineered rodent models and associated services, announced a strategic partnership.

Sinovant Sciences unveiled its drug pipeline

good laboratory practice
Sinovant Sciences, a Shanghai-based biopharmaceutical company dedicated to bringing innovative medicines to China and advancing Chinese biopharmaceutical innovation abroad, unveiled its pipeline and leadership team.

Novartis buys exclusive rights to a promising dermatologic drug

Novartis announced that it has entered into an exclusive license agreement with biotech companies Galapagos NV, Mechelen (Belgium) and MorphoSys AG, Planegg/Munich (Germany) regarding their compound MOR106.

Hong Kong Polytechnic University and Axis create a Joint Center for Immunotherapy

The Hong Kong Polytechnic University will join forces with Axis Therapeutics, a newly established joint venture by Athenex, Inc. and Xiangxue Pharmaceutical.

EUSA Pharma buys global rights to Sylvant drug from Janssen

EUSA Pharma announced that it has entered into a definitive agreement with Janssen Sciences Ireland UC, a subsidiary of Janssen R&D Ireland to acquire the global rights to SYLVANT® (siltuximab).

Sanofi and REVOLUTION Medicines entered an exclusive worldwide partnership

Sanofi and REVOLUTION Medicines announced an exclusive worldwide partnership to develop and commercialize targeted therapies, based on the biology of the cellular enzyme SHP2.

New Russian cancer treatment technology is ready for clinical trials

Scientists at the Institute of Cytology and Genetics in Novosibirsk have developed a technology for effective cancer treatment, which allows to reduce the dose of chemotherapy several-fold.

Takeda and Celgene invest in Presage Biosciences

Presage Biosciences, a cancer biotechnology company pioneering the use of intratumoral microdosing, announced that it has closed a Series D financing led by pharmaceutical companies Takeda and Celgene.

Chinese researchers made progress in development of Alzheimer’s disease drug

alzheimer's disease
GV-971 was developed by Ocean University of China, Shanghai Institute of Materia Medica under Chinese Academy of Sciences and Green Valley Pharmaceutical.

Russian drugs with precise delivery system may become available in five years

Intracellular drug delivery system was developed at the Institute of Theoretical and Experimental Biophysics of RAS. This principle is expected to be used to obtain highly effective anti-inflammatory drugs.

Verge Genomics receives $32 million financing to accelerate drug discovery

Verge Genomics, a drug discovery company utilizing machine learning to develop new therapeutics, announced that it has raised $32 million in Series A financing.

Scientists from Novosibirsk search for new ways of cancer treatment

In the laboratory of Research Institute of Clinical and Experimental Lymphology of the Siberian Branch of the Russian Academy of Sciences, chemists and biologists are working together to create a weapon against cancer.

Akebia Therapeutics and Keryx Biopharmaceuticals will merge

Akebia Therapeutics and Keryx Biopharmaceuticals announced that the companies signed, and the boards of directors of both companies have unanimously approved, a definitive merger agreement.

Russian scientists developed a combined cancer drug

Gene Surgery, a resident of SKOLKOVO, has conducted preclinical study of AntioncoRAN-M, an original cancer drug developed in Russia.

Isotopia and Bar-Ilan University intend to develop a new radioactive marker

The Israeli Isotopia Company, in collaboration with Prof. Rachela Popovtzer of Bar-Ilan University's Faculty of Engineering, is conducting a joint study to develop a radioactive marker for the detection of cancer.